Happy New Year! Our Highlights 2021 are...

2021 has been a year full of hopes, successes, setbacks and new beginnings due to the ongoing COVID-19 pandemic. Since more than 17 years, it has been our pleasure to provide you with our high quality peptides and peptide tools, and we want to express our deep gratitude for your trust and loyalty! We would not have been able to go through this crisis without your input: the continuous interaction with you, your comments, questions, recommendations and critiques supported us to keep innovating and improve.

Therefore, we are happy to share some of JPT’s 2021-highlights with you.

Wishing you a happy and healthy 2022,

Your JPT Team

• We are proud that JPT’s products contributed to the development of several SARS-CoV-2 vaccines and many important studies published in more than 100 papers

• Our new website was launched & has been well received among customers

• Keeping up with the development of emerging SARS-CoV-2 variants of concern has been a challenge. But so far we have launched products for the Alpha, Beta, Gamma, Delta, Epsilon and Kappa variants , with Lambda and Omicron coming very soon.

• Due to the high demand in our products and services we hired 30 new employees in 2021 and added more lab space to our facilities.

• We released a new line of PepMixes™ that combine immunodominant epitopes from all the antigens of one virus, e.g. SARS-CoV-2, EBV, HHV& and more. Therefore, you are able to elicit virus-specific strong immune responses .

• JPT’s scientists were authors and co-authors in 7 publications (among them two in Science and one in Nature)